default author photo

Seung Tae Kim

Sungkyunkwan University - Department of Medicine

Korea, Republic of (South Korea)

SCHOLARLY PAPERS

5

DOWNLOADS

326

TOTAL CITATIONS

1

Scholarly Papers (5)

1.

Atypical RAS Mutations in Metastatic Colorectal Cancer

Number of pages: 31 Posted: 13 Apr 2019
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Foundation Medicine, Inc., Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Foundation Medicine Inc., National Cancer Center Hospital East, Foundation Medicine Inc., Sungkyunkwan University - Department of Medicine, Catholic University of Milan - Fondazione Policlinico Universitario Agostino Gemelli, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Foundation Medicine, Inc., Foundation Medicine Inc., Sungkyunkwan University - Division of Hematology-Oncology, National Cancer Center Hospital East, University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department, University of Pisa - Department of Oncology, Memorial Sloan Kettering Cancer Center - Department of Pathology and University of Pisa - Department of Oncology
Downloads 100 (689,572)

Abstract:

Loading...

colorectal cancer; RAS mutations; atypical; anti-EGFR treatment; tumor mutational burden

2.

Genomic Characterization of Intrinsic and Acquired Resistance to Cetuximab in Colorectal Cancer Patients

Number of pages: 34 Posted: 04 Jan 2019
Eli Lilly and Company, Ltd, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - School of Medicine, Sungkyunkwan University, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Eli Lilly and Company, Ltd, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - School of Medicine, Eli Lilly and Company, Ltd, Sungkyunkwan University - Department of Surgery and Eli Lilly and Company, Ltd - Oncology Discovery Research
Downloads 70 (875,328)

Abstract:

Loading...

Cetuximab, Acquired Resistance, Colorectal Cancer

3.

Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Randomized, Phase Three, Non-Inferiority Trial

Number of pages: 60 Posted: 09 Aug 2018
Sungkyunkwan University - Department of Medicine, Gyeongsang National University - Department of Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Ajou University - Department of Medicine, Dong-A University - Department of Medicine, Chung-Ang University, College of Medicine, Department of Medicine, Catholic University of Korea - Department of Medicine, Inje University - Department of Medicine, Konkuk University - Department of Medicine, Yonsei University - Department of Medicine, Catholic University of Korea - Department of Medicine, Sungkyunkwan University - Statistics and Data CenterSungkyunkwan University - Department of Ophthalmology, Sungkyunkwan University - Statistics and Data Center, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Department of Medicine and Sungkyunkwan University - Department of Medicine
Downloads 55 (1,020,567)
Citation 1

Abstract:

Loading...

biliary tract cancer, capecitabine, oxaliplatin, gemcitabine

4.

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities

Number of pages: 108 Posted: 08 Nov 2018
Gachon University - Department of Internal Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Internal Medicine, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Internal Medicine, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Internal Medicine, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Internal Medicine, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Dermatology, Dong-A University - Department of Pulmonology, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Pathology, Gyeongsang National University, College of Medicine, Gyeongsang National University Hospital, Department of Internal Medicine, Gyeongsang National University, College of Medicine, Gyeongsang National University Hospital, Department of Internal Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - Department of Medicine, Soonchunhyang University, School of Medicine, Bucheon Hospital, Department of Internal Medicine, Chung-Ang University, College of Medicine, Department of Medicine, Chung-Ang University, College of Medicine, Department of Internal Medicine, Gachon University - Department of Internal Medicine, Kosin University, College of Medicine, Department of Medicine, Division of Hematology-Oncology, Pusan National University, School of Medicine, Yangsan Hospital, Department of Internal Medicine, Pusan National University, School of Medicine, Yangsan Hospital, Department of Internal Medicine, Soonchunhyang University, School of Medicine, Soonchunhyang University Hospital, Department of Internal Medicine, Dankook University, College of Medicine, Department of Internal Medicine and Dankook University, College of Medicine, Department of Internal Medicine
Downloads 51 (1,052,702)

Abstract:

Loading...

EGFR, EGF Ointment, Skin, Adverse Event, Quality of Life

5.

Systematic Evaluation of Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening

Number of pages: 23 Posted: 22 Aug 2019
Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - Institute for Refractory Cancer Research, Sungkyunkwan University - Division of Hematology-Oncology, Medical & Bio Device (MBD) Co., Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Medical & Bio Device (MBD) Co., Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Department of Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - School of Medicine, Sungkyunkwan University - Institute for Refractory Cancer Research and Sungkyunkwan University - Division of Hematology-Oncology
Downloads 50 (1,063,489)

Abstract:

Loading...

Tumour heterogeneity; Tumour purity; Patient-derived tumour cell; High-throughput drug screening; Two-drug combination